Amlexanox increases the level of a second messenger molecule called cAMP which then increases the rate by which cells burn fat… Researchers at the University of Michigan have identified how a promising drug in clinical trials for the treatment of obesity and related metabolic disorders improves the metabolism of sugar …
Read More »Obesity and CHD Association in Type 2 Diabetes Patients
Are obesity and CHD truly associated?… Researchers from the U.S. and China examined data on 30,434 diabetic patients from the Louisiana State University Hospital-Based Longitudinal Study (10,955 men and 19,479 women). Patients included were 30-95 years of age without a history of CHD or stroke in the Louisiana State University …
Read More »Barbara E. Corkey, PhD, Introduction: The Unknown Causes of Diabetes and Obesity
Dr. Barbara E. Corkey introduces herself and explains a little about the work she and her team do in her lab, examining the effects of various substances, both nutritional and non-food substances, on the human cell…. More videos with Dr. Corkey: Introduction: The Unknown Causes of Diabetes and Obesity What …
Read More »Barbara E. Corkey, PhD: Current Strategies to Combat Obesity Not Working
Dr. Barbara E. Corkey, talks about how the current dogma on how our obese patients should lose weight to combat diabetes is simply not working. She notes that we seem to be focusing too much on the wrong things – sending patients home with the advice to lose weight – …
Read More »New Guideline Released on Pharmacological Management of Obesity
The Endocrine Society has released a clinical practice guideline on the pharmacological management of obesity that includes recommendations on strategies for prescribing weight loss drugs.
Read More »FDA Approves Maestro Rechargeable System (EnteroMedics) for Treatment of Obesity.
The Maestro Rechargeable System is indicated for treatment of patients aged at least 18 years with a BMI of 35 to 45 with at least one obesity-related condition and who have failed to lose weight on a weight loss program. The novel device is the first to target the nerve …
Read More »Change Talk: Childhood Obesity
Change Talk: Childhood Obesity is a role-play simulation where you take the role of a healthcare provider and engage in a practice conversation with a virtual mother and her child. Through the conversation, you learn to apply Motivational Interviewing (MI) techniques to help them identify motivation for change, supporting them …
Read More »Beloranib Demonstrates Weight Loss in Hypothalamic Injury-Associated Obesity
The drug, a first-in-class MetAP2 inhibitor, was well-tolerated and also improved cardiovascular disease risk factors… Zafgen has announced that ZAF-221, a randomized, double-blind, placebo-controlled Phase 2 clinical trial of beloranib, a MetAP2 inhibitor, in 14 adults with hypothalamic injury associated obesity, or HIAO, met the primary efficacy endpoint of weight …
Read More »Obesity Not Unhealthy for Some
Obesity does not always go hand in hand with metabolic changes in the body that can lead to diabetes, heart disease and stroke, according to a new published study… In a study at Washington University School of Medicine, researchers found that a subset of obese people do not have common …
Read More »Obesity Risk Can Depend on Year of Birth
Before 1942, environmental factors were not as significant as in later years, when they are believed to be twice as strong… A multi-institutional research team at Massachusetts General Hospital has found out that environmental factors may outweigh genetic ones, as the risk of obesity that runs even in the same …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.